Key result
In a mouse model of LQT3, cholinergic stimulation provoked arrhythmias, whereas chronic flecainide pre-treatment and beta-adrenoceptor stimulation suppressed them (P<0.05).
Why the study?
Does autonomic modulation or antiarrhythmic therapy affect the occurrence of arrhythmias in a mouse model of long QT syndrome type 3?
Does autonomic modulation or antiarrhythmic therapy affect the occurrence of arrhythmias in a mouse model of long QT syndrome type 3?
p-value: p=< 0.05
In a mouse model of LQT3, cholinergic stimulation provokes arrhythmias via bradycardia, which are prevented by sodium channel blockade (flecainide) but not by beta-blockers.
No takes yet. Share an insight, caveat, or question.
Preclinical autonomic findings in LQT3 mice should not change practice; leaves open translation to human arrhythmia management.
Fabritz et al. (2010) studied Long QT syndrome type 3. Autonomic modulation and antiarrhythmic therapy (carbachol, beta-blockers, flecainide) was evaluated on Arrhythmias (bigemini and TdP) (p=< 0.05). In a mouse model of LQT3, cholinergic stimulation provoked arrhythmias, whereas chronic flecainide pre-treatment and beta-adrenoceptor stimulation suppressed them (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: